Gamma suppression correlates with thalamic stimulation therapeutic response in intractable epilepsy

Area of Science:

• Neuroscience
• Biomarkers
• Epilepsy Research

Background:

• Drug-resistant epilepsy poses challenges for treatment.
• Anterior nucleus of the thalamus (ANT) deep brain stimulation (DBS) is a therapeutic option.
• Current DBS therapy lacks real-time biomarkers for parameter selection and efficacy assessment.

Purpose of the Study:

• To identify novel electrophysiological biomarkers for ANT-DBS in drug-resistant epilepsy.
• To correlate local field potential (LFP) oscillations with therapeutic response.
• To guide stimulation parameter optimization for improved patient outcomes.

Main Methods:

• Retrospective analysis of ANT-LFP data from 11 patients in a prospective ANT-DBS trial.
• Recording of ANT LFPs during various stimulation settings.
• Comparison of LFP power spectral density during stimulation versus baseline.
• Correlation of SGO suppression with seizure frequency reduction (>50%).

Main Results:

• Seven participants exhibited slow gamma oscillations (SGOs) in the ANT.
• Six of these seven participants were responders to ANT-DBS.
• Progressive SGO suppression (
• gamma fade
• ") correlated with seizure reduction in responders.
• Acute stimulation suppressed SGOs in most responders, indicating potential for dynamic parameter adjustment.

Conclusions:

• SGO suppression in the ANT is a promising biomarker for ANT-DBS.
• This biomarker can aid in identifying responders and optimizing stimulation parameters.
• Biomarker-guided intervention offers potential for precise and effective epilepsy treatment.